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1 
PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
2 
or a pharmaceutically acceptable salt thereof wherein R 1 is 
---C1 _4 alky, optionally substituted with hydroxy. 
Specifically, a compound of formula I wherein R 1 is 
methyl. 
This application is a divisional of U.S. patent application 5 
Ser. No. 12/542,451 filedAug. 17, 2009, now allowed, which 
claims the benefit of priority to U.S. Provisional Application 
No. 61/090,371 filed Aug. 20, 2008, now abandoned. 
Specifically, a compound of formula I wherein R 1 is ethyl 
or cyclobutyl. 
In another aspect, the present invention also provides: 
pharmaceutical compositions which comprise a pharma-
ceutically acceptable carrier and a compound of formula I, 
methods for controlling or treating a disorder or condition FIELD OF THE INVENTION 
Described herein is N-methyl( 4-(methyl(7H-pyrrolo[2,3-
d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide, 
its analogues, their use as Janus Kinase (JAK) inhibitors, 
pharmaceutical compositions containing these compounds, 
and methods for the preparation of these compound. 
BACKGROUND OF THE INVENTION 
Protein kinases are families of enzymes that catalyze the 
phosphorylation of specific residues in proteins, broadly clas-
sified into tyrosine and serine/threonine kinases. Inappropri-
ate kinase activity, arising from mutation, over-expression, or 
inappropriate regulation, dys-regulation or de-regulation, as 
well as over- or under-production of growth factors or cytok-
ines has been implicated in many diseases, including but not 
limited to cancer, cardiovascular diseases, allergies, asthma 
and other respiratory diseases, autoimmune diseases, inflam-
matory diseases, bone diseases, metabolic disorders, and neu-
rological and neurodegenerative disorders such as Alzhe-
imer's disease. Inappropriate kinase activity triggers a variety 
of biological cellular responses relating to cell growth, cell 
differentiation, survival, apoptosis, mitogenesis, cell cycle 
control, and cell mobility implicated in the aforementioned 
and related diseases. 
Thus, protein kinases have emerged as an important class 
of enzymes as targets for therapeutic intervention. In particu-
lar, the JAK family of cellular protein tyrosine kinases (JAK-
1, JAK-2, JAK-3, and Tyk-2) play a central role in cytokine 
signaling (Kisseleva et al, Gene, 2002, 285, 1; Yamaoka et al. 
Genome Biology 2004, 5, 253)). Upon binding to their recep-
tors, cytokines activate JAK which then phosphorylate the 
cytokine receptor, thereby creating docking sites for signal-
ing molecules, notably, members of the signal transducer and 
activator of transcription (STAT) family that ultimately lead 
to gene expression. Numerous cytokines are known to acti-
vate the JAK family. 
Accordingly, there remains a need for alternative com-
pounds that effectively inhibit JAK enzymes, including JAK-
1, JAK-2, JAK-3, and/or Tyk-2. 
SUMMARY OF THE INVENTION 
The present invention provides a compound of formula I: 
H 
\ 
S/N-RI 
//~ 
'-.... 0 
N 
N~ l_jLN) 
N N I 
H 
10 
selected from organ transplant rejections, lupus, multiple 
sclerosis, rheumatoid arthritis, psoriasis, cancer, osteoarthri-
tis, and diabetes by administering to a mammal in need a 
therapeutically effective amount of a compound of formula I 
15 
or a pharmaceutically acceptable salt thereof, 
methods for controlling or treating a disorder or condition 
selected from diabetes, cancer, autoimmune thyroid disor-
ders, ulcerative colitis, Crohn's disease, dry eyes, Alzhe-
imer's disease, leukemia, and other indications where immu-
nosuppression or immunomodulation would be desirable by 
20 administering to a mammal in need a therapeutically effective 
amount of a compound of formula I or a pharmaceutically 
acceptable salt thereof, 
methods for controlling or treating a disorder or condition 
selected from allergic reaction including allergic dermatitis, 
25 eczema, atopic dermatitis, pruritus and other pruritic condi-
tions and inflammatory disease such as bowel disease in 
mammal by administering to a mammal in need a therapeu-
tically effective amount of a compound of formula I or a 
pharmaceutically acceptable salt thereof, 
methods for controlling or treating a disorder or condition 
30 
selected from Asthma and other obstructive airways diseases, 
including chronic or inveterate asthma, late asthma, airway 
hyper-responsiveness, bronchitis, bronchial asthma, allergic 
asthma, intrinsic asthma, extrinsic asthma, dust asthma, 
recurrent airway obstruction, and chronic obstruction pulmo-
35 nary disease by administering to a mammal in need a thera-
peutically effective amount of a compound of formula I or a 
pharmaceutically acceptable salt thereof, 
methods for the inhibition of protein tyrosine kinases or 
JAK-1, JAK-2, JAK-3 and/or Tyk-2 by administering to a 
40 mammal in need of a therapeutically effective amount of a 
compound of formula I or a pharmaceutically acceptable salt 
thereof, 
methods for the inhibition of protein tyrosine kinases or 
JAK-1, JAK-2, JAK-3 and/or Tyk-2 by administering to a 
45 mammal in need of a therapeutically effective amount of a 
compound of formula I or a pharmaceutically acceptable salt 
thereof, and methods for the preparation of compounds of the 
present invention. 
50 BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a characteristic X-ray powder diffraction pattern 
of N-methyl-1-{trans-4-[methyl(7H-pyrrolo[2,3-d]pyrimi-
din-4-yl)amino ]cyclohexyl}methanesulfonamide maleic 
55 acid salt (Form A). 
FIG. 2 illustrates Day 27VAS Scores for Example 1 bin flea 
allergic dogs in the Reducing Flea-associated Pruritus and 
Dermatitis Assay 
FIG. 3 illustrates Seconds of Pruritus per 4 hour recording 
60 for example 1 b in flea allergic dogs in the Reducing Flea-
associated Pruritus and Dermatitis Assay. 
DETAILED DESCRIPTION 
65 With respect to the above compound, and throughout the 
application and claims, the following terms have the mean-
ings defined below. 
US 8,987,283 B2 
3 4 
The term "mammal" refers to human or animals including 
livestock and companion animals. The phrase "companion 
animal" or "companion animals" refers to animals kept as 
pets. Examples of companion animals include cats, dogs, and 
5 horses. The term "livestock" refers to animals reared or raised 
in an agricultural setting to make products such as food or 
fiber, or for its labor. In some embodiments, livestock are 
suitable for consumption by marmnals, for example humans. 
Examples of livestock animals include mammals, such as 10 
cattle, goats, horses, pigs, sheep, including lambs, and rab-
bits, as well as birds, such as chickens, ducks and turkeys. 
The term "controlling", "treating" or "treatment" of a dis-
ease includes: (1) preventing the disease, i.e. causing the 15 
clinical symptoms or signs of the disease not to develop in a 
mammal that may be exposed to or predisposed to the disease 
but does not yet experience or display symptoms/signs of the 
disease; (2) inhibiting the disease, i.e., arresting or reducing 20 
the development of the disease or its clinical symptoms/signs; 
or (3) relieving the disease, i.e., causing regression of the 
disease or its clinical symptoms/signs. 
The term "therapeutically effective amount" means the 25 
IA 
or a pharmaceutically acceptable salt thereof. 
Included within the scope of the described compounds are 
all isomers ( e.g. cis-, trans-, or diastereomers) of the com-
pounds described herein alone as well as any mixtures. All of 
these forms, including enantiomers, diastereomers, cis, trans, 
syn, anti, solvates (including hydrates), tautomers, and mix-
tures thereof, are included in the described compounds. 
Stereoisomeric mixtures, e.g. mixtures of diastereomers, 
can be separated into their corresponding isomers in a known 
manner by means of suitable separation methods. Diastereo-
meric mixtures for example may be separated into their indi-
vidual diastereomers by means of fractionated crystalliza-
tion, chromatography, solvent distribution, and similar 
procedures. This separation may take place either at the level 
of one of the starting compounds or in a compound of formula 
amount of a compound that, when administered to a mammal 
for treating a disease, is sufficient to effect such treatment for 
the disease. The "therapeutically effective amount" will vary 
depending on the compound, the disease and its severity and 
the age, weight, etc., of the mammal to be treated. 30 I itself. Enantiomers may be separated through the formation 
of diastereomeric salts, for example by salt formation with an 
enantiomer-pure chiral acid, or by means of chromatography, 
for example by HPLC, using chromatographic substrates 
The term "approximately" if used in defining a peak in an 
X-ray powder diffraction pattern is defined as the stated 
2-theta value±0.2 degree 2-theta. Any determination of 
whether a crystalline form is the Form A polymorph and 35 
encompassed by the claims should be interpreted in light of 
the variability in this test. 
"Pharmaceutically acceptable" means suitable for use in 
mammals, companion animals or livestock animals. 
The carbon atom content of various hydrocarbon-contain-
ing moieties is indicated by a prefix designating the minimum 
and maximum number of carbon atoms in the moiety, i.e., the 
prefix C,_1 indicates a moiety of the integer "i" to the integer 
"j" carbon atoms, inclusive. Thus, for example, C1 _4 alkyl 
refers to alkyl of one to four carbon atoms, inclusive. 
The term alkyl refers to straight, branched and a cyclic 
with chiral ligands. 
Routes of Administration 
In therapeutic use for treating disorders in a mammal (i.e. 
human and animals), a compound of the present invention or 
its pharmaceutical compositions can be administered orally, 
parenterally, topically, rectally, transmucosally, or intesti-
40 nally. Parenteral administrations include indirect injections to 
generate a systemic effect or direct injections to the afflicted 
area. Topical administrations include the treatment of skin or 
organs readily accessibly by local application, for example, 
eyes or ears. It also includes transdermal delivery to generate 
45 a systemic effect. The rectal administration includes the form 
of suppositories. The preferred routes of administration are 
oral and parenteral. 
Pharmaceutical Salts 
saturated monovalent hydrocarbon groups, but reference to 50 
The compound of formula I may be used in its native form 
or as a salt. In cases where forming a stable nontoxic acid or 
base salt is desired, administration of the compound as a 
pharmaceutically acceptable salt may be appropriate. Phar-
maceutically acceptable salts of the compounds of formula I 
include the acetate, ascorbate, aspartate, benzoate, besylate, 
an individual radical such as "propyl" embraces only the 
straight chain radical, a branched chain isomer such as "iso-
propyl" or a cyclic isomer such as cyclopropylmethyl or 
cyclopentyl being specifically referred to. 
55 bicarbonate/carbonate, bisulphate/sulphate, borate, camsy-
late, citrate, edisylate, etoglutarate, esylate, formate, fuma-
rate, gluceptate, gluconate, glucuronate, glycerophosphate, 
hexafluorophosphate, hibenzate, hydrochloride/chloride, 
hydro bromide/bromide, hydroiodide/iodide, isethionate, lac-
Compounds that have the same molecular formula but 
differ in the nature or sequence of bonding of their atoms or 
the arrangement of their atoms in space are termed "isomers". 
Isomers that differ in the arrangement of their atoms in space 
are termed "stereoisomers". It will be appreciated by those 
skilled in the art that the compound of formula I can exist as 
cis- and trans-achiral diastereomers. Specifically, the present 
invention provides a compound of formula IA, which has the 
chemical name N-methyl-1-{trans-4-[methyl(7H-pyrrolo[2, 65 
3-d]pyrimidin-4-yl)amino] 
cyclohexy 1} methanesulfonamide, 
60 tate, malate, maleate, malonate, mesylate, methylsulphate, 
naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, 
palmitate, pamoate, phosphate/hydrogen phosphate/dihydro-
gen phosphate, saccharate, stearate, succinate, tartrate, tosy-
late and trifluoroacetate salts. 
Composition/Formulation 
Pharmaceutical compositions of the present invention may 
be manufactured by processes well known in the art, e.g., by 
US 8,987,283 B2 
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means of conventional mixing, dissolving, granulation, dra-
gee-making, levigating, emulsifying, encapsulating, entrap-
ping, lyophilizing processes or spray drying. 
6 
transplants, lupus, multiple sclerosis, rheumatoid arthritis, 
psoriasis, Type I diabetes and complications from diabetes, 
cancer, asthma, atopic dermatitis, autoimmune thyroid disor-
ders, ulcerative colitis, Crohn' s disease, Alzheimer's disease, 
5 leukemia, osteoarthritis, control of pruritus, chronic respira-
tory disease and other indications where immunosuppres-
sion/immunomodulation would be desirable. 
Pharmaceutical compositions for use in accordance with 
the present invention may be formulated in conventional 
manner using one or more pharmaceutically acceptable car-
riers comprising excipients and auxiliaries, which facilitate 
processing of the active compound into preparations, which 
can be used pharmaceutically. Proper formulation is depen-
dent upon the route of administration chosen. Pharmaceuti- 10 
cally acceptable excipients and carriers are generally known 
In addition, there are substantial needs for safe and effica-
cious agents to control atopic dermatitis in animals. The mar-
ket for treating atopic dermatitis in animals is currently domi-
nated by corticosteroids, which cause distressing and 
undesirable side effects in animals, specifically in companion 
animals such as dogs. Antihistamines are also used, but are 
to those skilled in the art and are thus included in the instant 
invention. Such excipients and carriers are described, for 
example, in "Remingtons Pharmaceutical Sciences" Mack 
Pub. Co., New Jersey (1991). 
The formulations of the invention can be designed to be 
short-acting, fast-releasing, long-acting, and sustained-re-
leasing. Thus, the pharmaceutical formulations can also be 
formulated for controlled release or for slow release. 
Dosage 
Pharmaceutical compositions suitable for use in the 
present invention include compositions wherein the active 
ingredients are contained in an amount sufficient to achieve 
the intended purpose, i.e., control or the treatment of disor-
ders or diseases. More specifically, a therapeutically effective 
amount means an amount of compound effective to prevent, 
alleviate or ameliorate symptoms/signs of disease or prolong 
the survival of the subject being treated. 
The quantity of active component, which is the compound 
of this invention, in the pharmaceutical composition and unit 
dosage form thereof, may be varied or adjusted widely 
depending upon the manner of administration, the potency of 
the particular compound and the desired concentration. 
Determination of a therapeutically effective amount is well 
within the capability of those skilled in the art. Generally, the 
quantity of active component will range between 0.01 % to 
99% by weight of the composition. 
Generally, a therapeutically effective amount of dosage of 
active component will be in the range of about 0.01 to about 
100 mg/kg of body weight/day, preferably about 0.1 to about 
10 mg/kg of body weight/day, more preferably about 0.3 to 3 
mg/kg of body weight/day, even more preferably about 0.3 to 
1.5 mg/kg of body weight/day It is to be understood that the 
dosages may vary depending upon the requirements of each 
subject and the severity of the disorders or diseases being 
treated. 
The desired dose may conveniently be presented in a single 
dose or as divided doses administered at appropriate intervals, 
for example, as two, three, four or more sub-doses per day. 
The sub-dose itself may be further divided, e.g., into a number 
of discrete loosely spaced administrations; such as multiple 
inhalations from an insufflator or by application of a plurality 
of drops into the eye. 
Also, it is to be understood that the initial dosage admin-
istered may be increased beyond the above upper level in 
order to rapidly achieve the desired plasma concentration. On 
the other hand, the initial dosage may be smaller than the 
optimum and the daily dosage may be progressively 
increased during the course of treatment depending on the 
particular situation. If desired, the daily dose may also be 
divided into multiple doses for administration, e.g., two to 
four times per day. 
Medical and Veterinary Uses 
Compounds of the present invention are Janus Kinase 
inhibitors (JAK-i) with efficacy against Janus Kinase- I (JAK-
1 ), Janus Kinase-2 (JAK-2) and Janus Kinase-3 (JAK-3). 
Accordingly, they are useful as therapeutic agents for organ 
15 poorly effective. A canine formulation of cyclosporine (ATOPICA ™) is currently being marketed for atopic derma-
titis, but is expensive and has a slow onset of efficacy. In 
addition, there are GI toleration issues with ATOPICA™. 
Compounds of present invention are JAK inhibitors with 
20 efficacy against JAK-1 and JAK-3. These compounds will be 
an alternative to steroid usage and provide resolution of 
chronic pruritus and inflammation that would either persist in 
atopic dermatitis or slowly regress following removal of aller-
gen or causative agent, such as fleas in flea-allergic dermati-
25 tis. 
Compounds of the present invention may be administered 
in a pharmaceutically acceptable form either alone or in com-
bination with one or more additional agents which modulate 
a mammalian immune system or with antiinflammatory 
30 agents. These agents may include but are not limited to 
cyclosporin A ( e.g. Sandimmune® or Neoral®, rapamycin, 
FK-506 (tacrolimus), leflunomide, deoxyspergualin, myco-
phenolate ( e.g. Cellcept®, azathioprine ( e.g. Imuran®), 
daclizumab (e.g. Zenapax®), OKT3 (e.g. Orthocolone®), 
35 AtGam, aspirin, acetaminophen, ibuprofen, naproxen, 
piroxicam, and antiinflanimatory steroids ( e.g. prednisolone 
or dexamethasone). These agents may be administered as part 
of the same or separate dosage forms, via the same or different 
routes of administration, and on the same or different admin-
40 istration schedules according to standard pharmaceutical 
practice known to one skilled in the art. 
In one embodiment, the invention provides methods of 
treating or preventing a disease, condition or disorder asso-
ciated with JAK in a subject, such as a human or non-human 
45 mammal, comprising administering an effective amount of 
one or more compounds described herein to the subject. The 
JAK associated disease, condition or disorder can be related 
to JAK-1, JAK-2, JAK-3, and/orTyk-2. Suitable subjects that 
can be treated include domestic or wild animals, companion 
50 animals, such as dogs, cats, horses and the like; livestock 
including, cows and other ruminants, pigs, poultry, rabbits 
and the like; primates, for example monkeys, such as rhesus 
monkeys and cynomolgus (also known as crab-eating or 
long-tailed) monkeys, marmosets, tamarins, chimpanzees, 
55 macaques and the like; and rodents, such as rats, mice, ger-
bils, guinea pigs and the like. In one embodiment, the com-
pound is administered in a pharmaceutically acceptable form, 
optionally in a pharmaceutically acceptable carrier. 
JAK/STAT signaling has been implicated in the mediation 
60 of many abnormal immune responses such as allergies, 
asthma, autoimmune diseases such as transplant (allograft) 
rejection, rheumatoid arthritis, amyotrophic lateral sclerosis 
and multiple sclerosis, as well as in solid and hematologic 
malignancies such as leukemia and lymphomas. For a review 
65 of the pharmaceutical intervention of the JAK/STAT pathway 
see Frank, (1999), Mo!. Med. 5:432:456 and Seidel et al., 
(2000), Oncogene 19:2645-2656. 
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JAK-3 in particular has been implicated in a variety of 
biological processes. For example, the proliferation and sur-
vival of murine mast cells induced by IL-4 and IL-9 have been 
shown to be dependent on JAK-3 and gamma chain-signal-
ing. Suzuki et al., (2000), Blood 96:2172-2180. JAK-3 also 
plays a crucial role in IgE receptor-mediated mast cell 
degranulation responses (Malaviya et al., (1999), Biochem. 
Biophys. Res. Commun 257:807-813), and inhibition of 
JAK-3 kinase has been shown to prevent type I hypersensi-
tivity reactions, including anaphylaxis (Malaviya et al., 
(1999), J. Biol. Chem. 274:27028-27038). JAK-3 inhibition 
has also been shown to result in immune suppression for 
allograft rejection (Kirken, (2001), Transpl. Proc. 33:3268-
3270). JAK-3 kinaseshavealso been implicated in the mecha-
nism involved in early and late stages of rheumatoid arthritis 
(Muller-Ladner et al., (2000), J. Immunal. 164:3894-3901); 
familial amyotrophic lateral sclerosis (Trieu et al., (2000), 
Biochem Biophys. Res. Commun. 267:22-25); leukemia 
(Sudbeck et al., (1999), Clin. Cancer Res. 5:1569-1582); 
mycosis fungoides, a form ofT-cell lymphoma (Nielsen et al., 
(1997), Prac. Natl. Acad. Sci. USA 94:6764-6769); and 
abnormal cell growth (Yu et al., (1997), J. Immunol. 159: 
5206-5210; Catlett-Falcone et al., (1999), Immunity 10: 105-
115). 
8 
topenia, sympathetic ophthalmia, myasthenia gravis, Graves' 
disease, primary biliary cirrhosis, chronic aggressive hepati-
tis, ulcerative colitis and membranous glomerulopathy, those 
designated as involving systemic autoimmune disorder, for 
5 example systemic lupus erythematosis, rheumatoid arthritis, 
Sjogren's syndrome, Reiter's syndrome, polymyositis-der-
matomyositis, systemic sclerosis, polyarteritis nodosa, mul-
tiple sclerosis and bullous pemphigoid, and additional 
autoimmune diseases, which can be O-cell (humoral) based 
10 or T-cell based, including Cogan's syndrome, ankylosing 
spondylitis, Wegener's granulomatosis, autoimmune alope-
cia, Type I or juvenile onset diabetes, and thyroiditis; 
Cancers or tumors, including alimentary/gastrointestinal 
tract cancer, colon cancer, liver cancer, skin cancer including 
15 mast cell tumor and squamous cell carcinoma, breast and 
mammary cancer, ovarian cancer, prostate cancer, lym-
phoma, leukemia, including acute myelogenous leukemia 
and chronic myelogenous leukemia, kidney cancer, lung can-
cer, muscle cancer, bone cancer, bladder cancer, brain cancer, 
20 melanoma including oral and metastatic melanoma, Kaposi's 
sarcoma, myelomas including multiple myeloma, myelopro-
liferative disorders, proliferative diabetic retinopathy, and 
angiogenic-associated disorders including solid tumors; 
Diabetes, including Type I diabetes and complications 
25 from diabetes; The JAK kinases, including JAK-3, are abundantly 
expressed in primary leukemic cells from children with acute 
lymphoblastic leukemia, the most common form of child-
hood cancer, and studies have correlated STAT activation in 
certain cells with signals regulating apoptosis (Demoulin et 
al., (1996), Mo!. Cell. Biol. 16:4710-6; Jurlander et al., 
(1997), Blood 89:4146-52; Kaneko et al., (1997), Clin. Exp. 
Immun 109:185-193; and Nakamura et al., (1996), J. Biol. 
Chem. 271: 19483-8). They are also known to be important to 
lymphocyte differentiation, function and survival. JAK-3 in 
particular plays an essential role in the function of lympho-
cytes, macrophages, and mast cells. Given the importance of 
this JAK kinase, compounds which modulate the JAK path-
way, including those selective for JAK-3, can be useful for 
treating diseases or conditions where the function oflympho-
cytes, macrophages, or mast cells is involved (Kudlacz et al., 40 
(2004)Am. J. Transplant4:51-57; Changelian (2003) Science 
302:875-878). 
Eye diseases, disorders or conditions including autoim-
mune diseases of the eye, keratoconjunctivitis, vernal con-
junctivitis, uveitis including uveitis associated with Behcet's 
disease and lens-induced uveitis, keratitis, herpetic keratitis, 
30 conical keratitis, corneal epithelial dystrophy, keratoleu-
koma, ocular premphigus, Mooren's ulcer, scleritis, Grave's 
ophthalmopathy, Vogt-Koyanagi-Harada syndrome, kerato-
conjunctivitis sicca ( dry eye), phlyctenule, iridocyclitis, sar-
coidosis, endocrine ophthalmopathy, sympathetic ophthalmi-
35 tis, allergic conjunctivitis, and ocular neovascularization; 
Intestinal inflammations, allergies or conditions including 
Crohn' s disease and/or ulcerative colitis, inflammatory bowel 
disease, coeliac diseases, proctitis, eosinophilic gastroenteri-
tis, and mastocytosis; 
Neurodegenerative diseases including motor neuron dis-
ease, Alzheimer's disease, Parkinson's disease, amyotrophic 
lateral sclerosis, Huntington's disease, cerebral ischemia, or 
neurodegenerative disease caused by traumatic injury, strike, 
glutamate neurotoxicity or hypoxia; ischemic/reperfusion 
Conditions in which targeting of the JAK pathway or 
modulation of the JAK kinases, particularly JAK-3, are con-
templated to be therapeutically useful include, arthritis, 
asthma, autoimmune diseases, cancers or tumors, diabetes, 
certain eye diseases, disorders or conditions, inflammation, 
intestinal inflammations, allergies or conditions, neurodegen-
erative diseases, psoriasis, transplant rejection, and viral 
infection. Conditions which can benefit for inhibition of 
JAK-3 are discussed in greater detail below. 
Accordingly, the compound of formula I or its pharmaceu-
tically acceptable salts and pharmaceutical compositions can 
be used to treat a variety of conditions or diseases such as: 
Arthritis, including rheumatoid arthritis, juvenile arthritis, 
and psoriatic arthritis; 
45 injury in stroke, myocardial ischemica, renal ischemia, heart 
attacks, cardiac hypertrophy, atherosclerosis and arterioscle-
rosis, organ hypoxia, and platelet aggregation; 
Skin diseases, conditions or disorders including atopic der-
matitis, eczema, psoriasis, scleroderma, pruritus and other 
50 pruritic conditions; 
Allergic reactions including allergic dermatitis in mammal 
including horse allergic diseases such as bite hypersensitivity, 
sUllliller eczema and sweet itch in horses. 
Transplant rejection, including pancreas islet transplant 
55 rejection, bone marrow transplant rejection, graft-versus-host 
disease, organ and cell transplant rejection such as bone mar-
row, cartilage, cornea, heart, intervertebral disc, islet, kidney, 
limb, liver, lung, muscle, myoblast, nerve, pancreas, skin, 
Asthma and other obstructive airways diseases, including 
chronic or inveterate asthma, late asthma, airway hyper-re-
sponsiveness, bronchitis, bronchial asthma, allergic asthma, 
intrinsic asthma, extrinsic asthma, dust asthma, recurrent air- 60 
way obstruction, and chronic obstruction pulmonary disease; 
small intestine, or trachea, and xeno transplantation; and 
Another embodiment provides a method of inhibiting a 
JAK enzyme, including JAK-1, JAK-2, JAK-3 and/orTyk-2, 
that includes contacting the JAK enzyme with either a non-
therapeutic amount or a therapeutically effective amount of 
one or more of the present compounds. Such methods can 
Autoimmune diseases or disorders, including those desig-
nated as single organ or single cell-type autoimmune disor-
ders, for example Hashimoto's thyroiditis, autoimmune 
hemolytic anemia, autoimmune atrophic gastritis of perni-
cious anemia, autoimmune encephalomyelitis, autoimmune 
orchitis, Goodpasture's disease, autoimmune thrombocy-
65 occur in vivo or in vitro. In vitro contact can involve a screen-
ing assay to determine the efficacy of the one or more com-
pounds against a selected enzyme at various amounts or con-
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This may be achieved by conventional methods, for example 
as described in "Protective Groups in Organic Synthesis" by 
T W Greene and PG M Wuts, John Wiley & Sons Inc (1999), 
and references therein. 
In Scheme I, 4-Chloro-7H-pyrrolo[2,3-d]pyrimidine (a) 
can be obtained commercially. trans-4-(Methylamino )-cy-
clohexyl]methanol (b) may be obtained from the correspond-
ing carboxylic acid, trans-4-[ ( tert-butoxycarbony 1 )amino ]cy-
clohexanecarboxy lic acid, upon treatment with a reducing 
centrations. In vivo contact with a therapeutically effective 
amount of the one or more compounds can involve treatment 
of a described disease, disorderor condition or prophylaxis of 
organ transplant rejection in the animal in which the contact 
occurs. The effect of the one or more compounds on the JAK 5 
enzyme and/or host animal can also be determined or mea-
sured. Methods for determining JAK activity include those 
described in the Examples as well as those disclosed in WO 
99/65908, WO 99/65909, WO 01/42246, WO 02/00661, WO 
02/096909, WO 2004/046112 or WO 2007/012953. 10 agent such as lithium aluminium hydride in an aprotic, anhy-
drous solvent such as tetrahydrofuran at temperatures 
between 0-60° C. for several hours. 
The following reaction schemes illustrate the general syn-
thetic procedures of the compounds of the present invention. 
All starting materials are prepared by procedures described in 
these schemes or by procedures known to one of ordinary 
skill in the art. 
f 
! 
g 
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N~ lJ-~> N N 
I 
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Scheme I 
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As shown in Scheme I, a compound of structure ( c) can be 
synthesized by the reaction of 4-chloro-7H-pyrrolo[2,3-d] 
pyrimidine (a) with trans-4-(methylamino )-cyclohexyl] 
D ,,,,, ·•'' "OH "-N 
N~ lJ-~> N N 
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It will be apparent to those skilled in the art that sensitive 65 methanol (b) in a suitable aprotic, polar solvent such as N,N-
functional groups (Pg or Pgl) may need to be protected and dimethylformamide, aqueous dioxane and 
deprotected during synthesis of a compound of the invention. dimethylsulfoxide, in the presence of a suitable base such as 
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triethylamine and potassium carbonate at elevated tempera-
tures up to 90° C. for up to a few hours. 
A compound of structure ( d) could be synthesized in a two 
step procedure from a compound of structure (c). For 
example, a compound of structure ( d) would be synthesized 5 
by firstly using brominating reagents such as thionyl bromide 
12 
be employed in a polar solvent such as acetic acid, if the 
reaction is performed in the presence of potassium acetate the 
potassium salt of the compound of formula (g) is produced. 
It is envisaged that a compound of structure (g) may be 
synthesized directly from a compound of structure ( e) upon 
treatment with a suitable sulfur nucleophile such as sodium 
sulfite in a polar solvent. Similarly, a compound of structure 
(g) could be synthesized from a compound of structure ( d) 
or phosphorous tribromide in a polar, aprotic solvent such as 
methylene chloride to afford the unprotected cyclohexylm-
ethylbromide, and secondly by addition of a suitable protect-
ing reagent such as tosyl chloride to give the protected com-
pound of structure ( d). 
10 upon nucleophilic substitution with sodium sulfite. 
A compound of structure ( e) can be prepared by using 
simple protection processes from a compound of structure 
Treatment of sulphonic acids of formula (g) with a chlori-
nating agent such as thionyl chloride in an aprotic, polar 
solvent such as methylene chloride with a polar cosolvent 
15 such as N,N-dimethylformamide at reflux gives the chlori-
nated compounds. The chlorinated compound then reacts in 
( c ). For example, when Pg and Pg1 are both tosyl, this can be 
effected in a one step reaction upon treatment of the unpro-
tected compound of structure (c) with tosyl chloride in the 
presence of a polar, aprotic solvent such as methylene chlo-
ride, a catalyst such as DMAP and a weak base such as 
20 
triethy !amine. 
A compound of structure (f) may be synthesized from a 
compound of structure ( e) by 
S-alkylation using a suitable nucleophile. Thus compounds 
of structure ( e) wherein the protecting group (PO is a suitable 25 
hydroxyl protecting group such as tosyl or mesyl may be 
reacted with potassium thioacetate in a polar solvent such as 
dimethylsulfoxide or N-methylpyrrolidine at elevated tem-
peratures up to 7 5° C. for up to 2 hours to give compounds of 
30 
structure (f). 
A compound of structure (g) may be synthesized by an 
oxidation procedure from compounds of formula (f). Many 
oxidizing conditions are known to those skilled in the art, for 
example those described in "Handbook of Reagents for 35 
Organic Synthesis-Oxidising and Reducing Agents" edited 
by S. D. Burke and R. L. Danheiser. For example, a compound 
of structure (f), optionally wetted with water, can be treated 
with formic acid followed by slow addition of hydrogen per-
oxide whilst stirring at room temperature for about 15 hours 40 
to give a compound of structure (g). Alternatively, oxone may 
an aprotic, anhydrous solvent such as tetrahydrofuran with 
suitable amines in neat, gaseous form, or dissolved in an 
aprotic, anhydrous solvents such as tetrahydrofuran, at room 
temperature to produce a compound of structure (h). Option-
ally an anhydrous, weak base such as triethylamine may be 
used to mop up hydrochloric acid generated in the reaction. 
Compounds of formula I of the present invention may be 
prepared from compounds of formula (h) wherein Pg is a 
suitable protecting group by deprotection procedures known 
to one skilled in the art. For example, when the protecting 
group (Pg) is tosyl, suitable deprotection conditions involve 
reaction with a base such as lithium hydroxide or potassium 
hydroxide in a protic solvent such as methanol or isopropanol 
and optionally miscible cosolvents such as tetrahydrofuran 
and water at room temperature for several hours, to produce 
the deprotected amine of formula I. 
Salts of compounds of formula I may be formed by the 
reaction of the free base of compounds of formula I with a 
suitable acid such as maleic acid in the presence of a protic 
solvent such as butanol and optionally a cosolvent such as 
water. 
Alternatively, compounds of this invention can be prepared 
in accordance with Scheme II. 
Scheme II 
/OH Cbyw 
N N 
I 
Pg /NH 
b k 
/ 
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In Scheme II, 4-methy 1-7 -[ ( 4-methy !phenyl )sulfony I]-7H-
pyrrolo [2,3-d]pyrimidine (j) can be obtained from commer-
cially available (a) using a protecting agent such as tosyl 20 
chloride using procedures well known in the art. trans-4-
(Methylamino )-cyclohexyl]methanol (b) may be obtained 
from the corresponding carboxylic acid, trans-4-[(tert-bu-
toxycarbonyl)amino ]cyclohexanecarboxylic acid, upon 25 
treatment with a reducing agent such as Vitride in an anhy-
drous solvent such as toluene at temperatures between 0-110° 
C. for several hours. 
As shown in Scheme II, a compound of structure (k) can be 30 
synthesized by the reaction of 4-chloro-7H-pyrrolo[2,3-d] 
pyrimidine (j) with trans-4-(methylamino )-cyclohexyl] 
methanol (b) in a suitable solvent such as acetone, in the 
presence of a suitable base such as triethylamine with a cata- 35 
lytic amount of potassium iodide at elevated temperatures up 
to 60° C. for up to a few hours. 
A compound of structure (k) could synthesized by addition 
of a suitable mesylating reagent such as mesyl chloride in the 40 
presence of a suitable base such as triethylamine or diethyl-
isopropylamine in a suitable solvent such as acetone at 
elevated temperatures up to 60° C. to give the methane sul-
fonyl compound of structure (k). 
A compound of structure (I) can be prepared by using 
simple S-alkylation processes from a compound of structure 
(k) using a suitable nucleophile. Thus compounds of structure 
45 
(k) may be reacted with sodium sulphite in solvent such as 50 
isopropylalcohol or water or toluene at elevated temperatures 
up to 90° C. for up to 4 hours to give compounds of structure 
(1 ). 
Treatment of sulphonic acids of formula (I) with a chlori- 55 
nating agent such as thionyl chloride in an aprotic, polar 
solvent such as THF or methylene chloride with a polar 
cosolvent such as N,N-dimethylformamide at temperatures 
between O and 40° C. gives the chlorinated compounds. The 60 
chlorinated compound then reacts in an aprotic, anhydrous 
solvent such as tetrahydrofuran with suitable amines such as 
methyl amine, cyclobutyl amine or 2-hydroxyazetidine pref-
erably in neat, gaseous form, or dissolved in an aprotic, anhy- 65 
drous solvents such as tetrahydrofuran, at room temperature 
to produce a compound of structure (h). Optionally an anhy-
14 
drous, weak base such as triethylamine may be used to mop 
up hydrochloric acid generated in the reaction. 
EXAMPLES 
Preparation 1 N-Methyl-l-[trans-4-(methyl {7-[(4-
methy lpheny I )sulfony I]-7H-pyrrolo [2,3-d]pyrimidin-
4-y l }amino )cyclohexyl]methanesulfonamide 
Method (a) To a solution of the compound of Preparation 2 
(308.0 gwetweight, 214.5 g dry weight, 0.41 mo!) in tetrahy-
drofuran (1.0 I) is added methylamine (2M in tetrahydrofu-
ran, 687 ml) over 1 h. After stirring at room temperature for 30 
min, additional methylamine (2M in tetrahydrofuran, 53 ml) 
is added and the reaction mixture is stirred at room tempera-
ture for 18 h. The mixture is reduced in volume to 600 ml, via 
vacuum distillation, and tetrahydrofuran (300 ml) is added, 
before the mixture is again reduced in volume to approxi-
mately 750 ml. To the mixture, heated at 45° C., is added 
2-propanol (247 ml) and water (693 ml). After cooling to 
room temperature, the solid material is collected by filtration, 
washed with water (2x250 ml) and dried in vacuo at 65° C. to 
give the title compound (180.4 g). 
1H-NMR (d6-DMSO): 1.17-1.32 (2H), 1.57-1.73 (4H), 
1.76-1.92 (lH), 1.93-2.08 (2H), 2.30-2.39 (3H), 2.53-2.62 
(3H), 2.87-2.98 (2H), 3.07-3.17 (3H), 4.53-4.75 (lH), 6.81-
6.94 (lH), 7.38-7.47 (2H), 7.56-7.65 (lH), 7.92-8.02 (2H), 
8.15-8.27 (lH). 
Method (b) To a solution of the compound of Preparation 2 
(165 g, 0.34 mo!) in THF (1.65 I) and N,N-dimethylforma-
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mide (5.0 ml) at 0-5° C. is added thionyl chloride (125 ml, 17 
mo!), over 25 min. The reaction mixture was stirred for 30 
minutes at 0-5° C. then slowly heated to 40° C. for 8 h. After 
cooling to r.t. the solvent was evaporated under reduced pres-
sure and azeotroped with THF to removed thionyl chloride. 5 
To the sulphonyl chloride obtained was added fresh THF 
(1.65 I) and the mixture cooled to 0° C. Dry N-methylamine 
gas was purged for 30 minutes and the reaction stirred for a 
further 4 hours at r.t. The solvent was evaporated to half of its 
volume (800 ml) and heptane (1.5 I) added. The product 10 
precipitated out and was filtered and washed with water (1 I) 
to give the title compound (80 g). 
1H-NMR (dcDMSO): 1.17-1.32 (2H), 1.57-1.73 (4H), 
1.76-1.92 (lH), 1.93-2.08 (2H), 2.30-2.39 (3H), 2.53-2.62 15 
(3H), 2.87-2.98 (2H), 3.07-3.17 (3H), 4.53-4.75 (lH), 6.81-
6.94 (lH), 7.38-7.47 (2H), 7.56-7.65 (lH), 7.92-8.02 (2H), 
8.15-8.27 (lH) 
Preparation 2 [trans-4-(Methyl {7-[(4-methylphenyl) 
sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl }amino) 
cyclohexyl]methanesulfonyl chloride 
20 
25 
30 
35 
40 
16 
with heptane (2x125 ml) to give the title compound (308.0 g 
wet weight), which is stored under nitrogen and used directly. 
Preparation 3 [trans-4-(Methyl {7-[(4-methylphenyl) 
sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl }amino) 
cyclohexyl]methanesulfonic acid 
.0 ,,,, ....... ··•' 'S03H '-....N 
CD 
N N 
I 
O=S=O ¢ 
Method (a) To a mixture of the compound of Preparation 4 
(100.0 g wet weight, 23.5 g dry weight, 47.8 mmol) and 
formic acid (82.0 g, 68.0 ml, 1.8 mo!) is added hydrogen 
peroxide (35 wt.% in water, 21.0 ml, 0.26 mo!) over l0min. 
45 The reaction mixture is stirred at room temperature for 15 h 
and then quenched by addition to an aqueous sodium met-
abisulfate or metabisulfite solution (33 wt. %, 35 ml). To the 
mixture is added water (5 ml), 2-propanol (50 ml) and aque-
ous sodium hydroxide solution (33 wt.%, 161 ml) and the 
To a solution of the compound of Preparation 3 (210.0 g, 
0.42 mo!) in dichloromethane (1.2 I) and N,N-dimethylfor-
mamide (4.1 ml) is added thionyl chloride (151.0 ml, 2.1 
mo!), over 25 min. The reaction mixture is heated at reflux for 
18 h and then reduced in volume to 800 ml, via vacuum 
distillation. To the mixture, heated at approximately 30° C., is 
added ethyl acetate (1.11) over 1 h, followed by heptane (546 
ml), added over 20 min at room temperature. The mixture is 
cooled to 0° C. and stirred for 1 hand the resulting precipitate 
is collected by filtration under nitrogen. The solid is washed 
50 slurry is stirred at room temperature for 1 h. The solid material 
is collected by filtration, washed with water (100 ml) and 
dried in vacuo at 60° C. to give the title compound (26.0 g). 
1H-NMR (dcDMSO): 0.98-1.18 (2H), 1.55-1.76 (5H), 
55 1.99-2.13 (2H), 2.29-2.39 (5H), 3.05-3.15 (3H), 4.47-4.76 (lH), 6.77-6.92 (lH), 7.38-7.48 (2H), 7.54-7.62 (lH), 7.91-
8.02 (2H), 8.17-8.25 (lH) 
Method (b) To a solution of the compound of Preparation 3 
in IPA-water (585 ml each, 1:1, VAT) was added sodium 
60 sulphate and the mixture was heated to 80-90° C. for 24 hours. 
After allowing to cool to r.t. the solvent was evaporated up to 
50% and the pH of the reaction mixture adjusted in the range 
3-4 by addition of acetic acid. Toluene (11) was added and the 
mixture evaporated to 80%. Further toluene (1 I) was added 
65 and the mixture refluxed for 4 hours. The toluene was 
decanted and the resultant title compound obtained by drying 
under vacuum (168 g). 
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1H-NMR (dcDMSO): 0.98-1.18 (2H), 1.55-1.76 (5H), 
1.99-2.13 (2H), 2.29-2.39 (5H), 3.05-3.15 (3H), 4.47-4.76 
(lH), 6.77-6.92 (lH), 7.38-7.48 (2H), 7.54-7.62 (lH), 7.91-
8.02 (2H), 8.17-8.25 (lH) 
Preparation 4 S-{[trans-4-(Methyl {7-[(4-methylphe-
nyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-
yl }amino )cyclohexyl]methyl }ethanethioate 
10 
15 
20 
25 
30 
18 
(2H), 3.06-3.14 (3H), 4.44-4.76 (lH), 6.76-6.94 (lH), 7.36-
7.49 (2H), 7.56-7.62 (lH), 7.90-8.02 (2H), 8.17-8.26 (lH) 
Preparation 5 [trans-4-(Methyl {7-[(4-methylphenyl) 
sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl }amino) 
cyclohexyl]methyl 4-methylbenzenesulfonate 
To a solution of the compound of Preparation 6 ( 42.0 g, 
0.16 mo!) in dichloromethane (11) is added triethylamine 
(68.3 g, 0.68 mo!) and 4-dimethylaminopyridine (1.0 g, 8.2 
mmol), followed by p-toluenesulfonyl chloride (62 g, 0.33 
35 mo!). The reaction mixture is stirred at room temperature for 
2 h, before addition of further p-toluenesulfonyl chloride 
(45.5 g, 0.24 mo!). After stirring for 18 h, the mixture is 
concentrated in vacuo and a portion of the residue (approxi-
mately 309 g) is slurried in methanol (758 ml) for 15 min. To 
40 the slurry is added water (600 ml) and saturated aqueous 
sodium hydrogen carbonate solution (142 ml) and the mix-
ture is stirred for 1 h. The solid material is collected by 
filtration and washed withmethanol:water [1: 1, 50 ml], water 
(50 ml) andhexanes (50 ml). The solid is dried in vacuo at 60° 
45 C. to give the title compound (87.1 g). 
50 
55 
1H-NMR (dcDMSO): 1.02-1.20 (2H), 1.53-1.75 (7H), 
2.31-2.39 (3H), 2.39-2.47 (3H), 3.04-3.12 (3H), 3.80-3.91 
(2H), 4.34-4.76 (lH), 6.78-6.93 (lH), 7.37-7.54 (4H), 7.54-
7.64 (lH), 7.75-7.84 (2H), 7.91-8.01 (2H), 8.14-8.25 (lH) 
Preparation 6 { trans-4-[Methyl(7H-pyrrolo[2,3-d] 
pyrimidin-4-yl)amino]cyclohexyl}-methanol 
To a solution of potassium thioacetate (11.4 g, 99.4 mmol) 
in dimethyl sulfoxide (30 ml) is added the compound of 
Preparation 5 (50.0 g, 87 .9 mmol) in dimethyl sulfoxide (130 
ml). The reaction mixture is heated at 55° C. for 3 h, cooled to 
60 
room temperature and quenched by addition to an aqueous 
sodium hydrogen carbonate solution (0.lM, 640 ml). The 
mixture is cooled to 13° C. and the resulting precipitate is 
collected by filtration and washed with water (250 ml) to give 
the title compound (204.0 g wet weight). 
1H-NMR (dcDMSO): 1.06-1.23 (2H), 1.39-1.51 (lH), 
1.51-1.70 (4H), 1.74-1.88 (2H), 2.30-2.40 (6H), 2.73-2.84 
65 
A mixture of the compound oftrans-4-(Methylamino)cy-
clohexyl]methanol (may be prepared according to the proce-
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dure described in WO 2002/14267)(50.0 g, 0.35 mo!), 
4-chloro-7H-pyrrolo[2,3-d]pyrimidine ( commercially avail-
able, 42.9 g, 0.27 mo!) and potassium carbonate (57 .3 g, 0.42 
mo!) in water (1 I) and 1,4-dioxane (100 ml) is heated at 90° 
C. for 15 h. To the mixture is added the compound of Prepa- 5 
ration 7 (2.0 g, 14.0 mmol) and the reaction mixture is heated 
at 90° C. for a further 1 h. After cooling to room temperature, 
the mixture is stirred for 1 hand the solid material is collected 
by filtration, washed with water (150 ml) and dried in vacuo 
at 65° C. to give the title compound (72.7 g). 10 
1H-NMR (dcDMSO): 1.00-1.19 (2H), 1.30-1.45 (lH), 
1.52-1.77 (4H), 1.77-1.91 (2H), 3.09-3.20 (3H), 3.20-3.29 
(2H), 4.37-4.51 (lH), 6.45-6.57 (lH), 7.06-7.17 (lH), 8.01-
8.14 (lH) 15 
20 
1H-NMR (dcDMSO): 
Preparation 8 
[ trans-4-(Methy !amino )cyclohexy !]methanol 
Vitride solution ( 65%, 7 67 ml, 2.465 mo!) was added drop-
Preparation 7 [trans-4-(Methyl {7-[(4-methylphenyl) 
sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl }amino) 
cyclohexyl]methanesulfinate 20 wise over 1 h to a solution oftrans-4-[(tert-butoxycarbonyl) 
amino ]cyclohexanecarboxylic acid ( commercially available, 
100 g, 0.4109 mo!) in toluene (1 I). After the addition was 
complete the reaction mixture was heated to reflux for 100-
1100 C. The reaction mixture was quenched withaq. Sodium 
25 sulphate solution (800 ml) at temperatures below 10° C. The 
reaction mixture was filtered through celite and the filter cake 
washed with DCM (500 ml) followed by water (100 ml). The 
organics layer was separated and the aqueous layer extracted 
twice with DCM (600 ml then 400 ml). The combined organ-
30 ics layers were dried over sodium sulphate and concentrated 
in vacuo to give the title compound (62 g). 
35 
40 
45 
50 
To a solution of the compound of Preparation 4 (60.0 g, 55 
0.418 mo!) in acetone (600 ml) is added triethylamine (117.5 
ml, 0.837 mo!) and catalytic potassium iodide (3.4 g, 0.05 
mo!), followed by 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 
(commercially available, 102.8 g, 0.335 mo!). The resulting 
mixture was heated to 60° C. for 22 h. After allowing to cool 60 
to r.t. acetone (300 ml) was added, followed by triethylamine 
(146.9 ml, 1.04 mo!) then mesyl chloride (81.7 ml, 1.047 
mo!). After stirring for 4 hours at r.t. water was added (1.81) 
whereupon the product precipitated out. The product was 
filtered, dried and triturated with a mixture ofMTBE-heptane 65 
(6:4, 600 ml). A second trituration from MTBE-heptane was 
conducted and the resultant title compound obtained ( 120 g). 
1H-NMR(CD3OD): 1.08-1.31 (4H), 1.51-1.64(1H), 1.93-
2.05 (2H), 2.10-2.22 (2H), 2.38-2.50 (lH), 2.50-2.54 (3H), 
3.48-3.55 (2H) 
Example la 
Preparation of N-methyl-1-{ trans-4-[ methyl(7H-
pyrrolo[2,3-d]pyrimidin-4-yl)amino] 
cyclohexyl} methanesulfonamide 
To a solution of the compound of Preparation 1 (250.0 g, 
0.48 mo!) in 2-propanol (1.2 I) is added lithium hydroxide 
(48.7 g, 2.03 mo!) in water (1.2 I). The reaction mixture is 
heated at 40° C. for 8 h and then stirred at room temperature 
for 18 h. The mixture is filtered, washing through with 2-pro-
panol:water (1: 1, 100 ml) and the filtrate is adjusted to pH 7.5 
by addition of hydrochloric acid (6N). After stirring for 1 h, 
the solid material is collected by filtration, washed with 
2-propanol:water (1 :2, 240 ml) and dried in vacuo at 60° C. to 
give the title compound (148.7 g) as a free base (Example la). 
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1H-NMR (dcDMSO): 1.20-1.39 (2H), 1.62-1.75 (4H), 
1.77-1.91 (lH), 1.97-2.11 (2H), 2.54-2.63 (3H), 2.89-2.99 
(2H), 3.10-3.21 (3H), 4.44-4.86 (lH), 6.43-6.61 (lH), 7.01-
7.19 (lH), 7.94-8.16 (lH) 
Example lb 
Preparation ofN-methyl-1-{ trans-4-[methyl(7H-
pyrrolo[2,3-d]pyrimidin-4-y !)amino] 
cyclohexy} methanesulfonamide maleic acid salt 10 
A mixture of the compoundofExample la (212.0 g, 628.3 
mmol) and maleic acid (67.2 g, 579.0 mmol) in 1-butanol 
(3200 ml) and water (400 ml) is stirred at room temperature 
15 for 18 h. The mixture is reduced in volume to 1600 ml, via 
vacuum distillation (55° C., 100 mbar) and then cooled to 0° 
C. The resulting solid is collected by filtration, washed with 
heptane (500 ml) and dried in vacuo at 35° C. to give the 
maleate salt of N-methyl-1-{trans-4-[methyl(7H-pyrrolo[2, 
20 3-d]pyrimidin-4-yl)amino]-
cyclohexyl}methanesulfonamide (253.0 g) as a crystalline 
form known as Form A. 
Experimental MH+ 338.2; expected 338.2. 
1H-NMR (dcDMSO): 1.24-1.38 (2H), 1.68-1.92 (5H), 
2.00-2.11 (2H), 2.56-2.61 (3H), 2.91-3.00 (2H), 3.15-3.27 25 
(3H), 4.39-4.70 (lH), 6.53-6.73 (lH), 7.16-7.36 (lH), 8.07-
8.29 (lH). 
Example le 
Method for collecting powder X-ray diffraction for 
N-methyl-1-{ trans-4-[ methyl(7H-pyrrolo[2,3-d]pyri-
midin-4-yl)amino ]cyclohexyl }-methanesulfonamide 
maleic acid salt (Form A) 
30 
35 
The powder X-ray diffraction patterns for Form A, N-me-
thyl-1-{ trans-4-[ methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl) 
amino ]cyclohexyl}-methanesulfonamide maleic acid salt 
were collected using a Bruker-AXS Ltd. D4 powder X-ray 
diffractometer fitted with an automatic sample changer, a 40 
theta-theta goniometer, automatic beam divergence slit, and a 
PSD Vantec-1 detector. The sample was prepared for analysis 
TABLE I-continued 
Powder X-ray Diffraction Peaks expressed in 
degrees 2-theta, ±0.2 degrees, approximately 
Angle Intensity 
2-theta I% 
20.659 27.8 
21.583 11.1 
22.642 12.7 
23.08 12.1 
24.86 19.8 
25.602 10.7 
26.582 13 
27.02 30.6 
27.721 18.7 
28.161 23.7 
28.38 28.9 
TABLE2 
Selected Powder X-ray Diffraction Peaks expressed 
in degrees 2-theta, ±0.2 degrees, approximately 
Angle Lattice Dimension Intensity 
2-theta d(A) I% 
6.179 14.3 73 
12.601 7.01 88 
15.719 5.63 100 
18.539 4.78 45 
27.02 3.29 30.6 
28.38 3.14 28.9 
As is readily apparent to one skilled in the art, the results of 
any X-ray powder diffraction may vary and subsequent 
XRPD's will not be identical, even when carried out on the 
by mounting on a low background cavity silicon wafer speci-
men mount. The specimen was rotated whilst being irradiated 
with copper K-alpha1 X-rays (wavelength=l.5406 Ang- 45 
stroms) with the X-ray tube operated at 40 kV/35 mA. The 
analyses were performed with the goniometer running in 
continuous mode set for a 0.2 second count per 0.018° step 
over a two theta range of 2° to 55°. The results are summa-
rized in Table 1 and Table 2. 50 same lot of material. This variance can be due to test sample 
TABLE 1 
Powder X-ray Diffraction Peaks expressed in 
degrees 2-theta, +0.2 degrees, approximately 
Angle Intensity 
2-theta I% 
6.178 72.6 
8.519 24.5 
12.601 88.4 
13.819 38 
15.478 34.3 
15.719 100 
16.32 27.1 
17.997 32.3 
18.539 44.5 
20.298 18.2 
55 
60 
preparation, temperature, the particular model of X-ray dif-
fractometer used, the operator's technique, etc. The term 
"approximately" if used in defining a peak in an X-ray pow-
der diffraction pattern is defined as the stated 20 
value±0.2°28. Any determination of whether a crystalline 
form is the Form A polymorph and encompassed by the 
claims should be interpreted in light of the variability in this 
test. 
This variability is demonstrated in FIG. 1. The two differ-
ent lots of N-methyl-1-{trans-4-[methyl(7H-pyrrolo[2,3-d] 
65 pyrimidin-4-y !)amino ]cyclohexy I }-methanesulfonamide 
maleic acid salt Form A were submitted to the same XRPD 
diffractometer. The characteristic peaks in FIG. 1 confirming 
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that it is the Form A polymorph. However, the relative inten-
sity of these peaks as well as the other identifying peaks 
varied slightly. 
Example 2 
Preparation of N-cyclobutyl-1-{ trans-4-[ methyl(7H-
pyrrolo[2,3-d]pyrimidin-4-y !)amino] 
cyclohexyl} methanesulfonamide 
Following the general procedure of Example 1 and making 
non-critical variations but substituting the precursor to 
cyclobutanamine, the title compound is provided. 
Experimental MH+ 378.0; expected 378.2 
1H-NMR (dcDMSO): 1.22-1.32 (2H), 1.47-1.70 (6H), 
1.78-2.04 (5H), 2.16-2.24 (2H), 2.85-2.86 (2H), 3.15 (3H). 
3.68-3.78 (lH), 4.60-4.72 (lH), 6.51-6.54 (lH), 7.11-7.12 
(lH), 7.44-7.49 (lH), 8.08 (lH), 11.60 (lH) 
Example 3 
Preparation ofN-ethyl-1-{ trans-4-[ methyl(7H-pyr-
rolo[2,3-d]pyrimidin-4-yl)amino] 
cyclohexyl} methanesulfonamide 
Following the general procedure of Example 1 and making 
non-critical variations but substituting the precursor to etha-
24 
chased from (Invitrogen Corporation, Madison, Wis.). 
Recombinant JAK-1 (GST-JAK-1 (852-1142)) and Tyk-2 
(GST-Tyk2 (870-1187, C1187S)) used in this study were 
expressed and purified at Pfizer Laboratories. Adenosine 
5 5'-triphosphate (ATP) was obtained from Sigma Chemical 
Company, St. Louis, Mo. The JAKtide peptide (peptide 
sequence, FITC-KGGEEEEYFELVKK (SEQ ID NO:1)) 
used for the JAK-2 and JAK-3 assays and the IRS-1 peptide 
(peptide sequence, 5-FAM-KKSRGDYMTMQIG (SEQ ID 
10 
NO:2)) used for the JAK-1 and Tyk-2 assays were purchased 
from (American Peptide Company, Sunnyvale, Calif.). Coat-
ing Reagent 3 was purchased from (Caliper Life Sciences, 
Hopkinton, Mass.). 
Methods: A peptide mobility shift assay was used to quan-
tify the phosphorylation of the JAKtide ( JAK-2 and JAK-3) or 
15 the IRS-1 peptide (JAK-1 and Tyk-2). Reactions were carried 
out in a 384-well plate (Matrical MP-101) in a 10 microliter 
total volume. Reaction mixtures contained 20 mM HEPES, 
pH 7.4, 10 mM magnesium chloride, 0.01 % bovine serum 
albumin (BSA), 0.0005% Tween-20, ATP ( 4 micromolar for 
20 JAK-2 andJAK-3, 40micromolarfor JAK-1 and 7 micromo-
lar for Tyk-2)), 2% DMSO and 1 micromolar peptide sub-
strate (JAKtide for JAK-2 and JAK-3 or IRS-1 peptide for 
JAK-1 and Tyk-2). Compounds were diluted serially in 100% 
dimethyl sulfoxide and tested in an 11 point dose response in 
25 duplicate or quadruplicate (200 nl of compound/DMSO was 
added per 10 microliterreaction). The reactions were initiated 
by the addition of enzyme to the final concentration of 2 nM 
JAK-2, 1 nM JAK-3, 7 nM Tyk2 or 20 nM JAK-1. The assay 
was run for 240 minutes for JAK-1, 150 minutes for JAK-2, 
30 
90 minutes for JAK-3 and 60 minutes for Tyk-2. The assays 
were stopped at the specified times with 20 microliter of 140 
mM HEPES, 22.5 mM EDTA and 0.15% Coating Reagent 3. 
The plates were placed on a LabChip 3000 (LC3000) instru-
ment (Caliper Life Sciences) to measure the formation of 
phosphorylated peptide. Data was analyzed using Hits Well 
35 Analyzer Software from (Caliper Life Sciences) to obtain the 
amount of product formed. 
Data was then imported into an internal application where 
each data point was expressed as% inhibition based on unin-
hibited and no enzyme controls. Dose-response data was then 
40 fit using a 4 parameter logistic equation (Equation 1) to deter-
mine an IC50 value. 
45 
50 
max-min 
y= (x)s+min 
1+-
/Cso 
Equation 1 
Where max is the fitted uninhibited value, min is the fitted 
complete inhibition value, and s is the slope factor. 
Using this protocol, the following results were generated 
for the title compounds of Example 1 and 2. 
TABLE3 
namine, the title compound is provided. 55 JAK Enzymatic Assay Result 
Experimental MH+ 352.0; expected 352.2 
1H-NMR (CDCl3 ): 1.24-1.44 (5H), 1.64-1.74 (2H), 1.87-
2.09 (3H), 2.15-2.21 (2H), 2.97-2.99 (2H), 3.18-3.27 (5H), 
4.46-4.52 (lH), 4.74-4.86 (lH), 6.55 (lH), 7.04 (lH), 8.28 
(lH) 60 
Example 4 
JAK Enzymatic Assay 
65 
Materials: Recombinant JAK-2 (Catalog Number 
PV4210) and JAK-3 (Catalog Number PV3855) were pur-
Ex.# 
la 
2 
JAK-1 ICso JAK-2 ICso 
9.53 nM 17.5 nM 
45.0 nM 101.0 nM 
Example 5 
JAK-3 IC50 
95.1 nM 
742 nM 
Tyk-2 IC50 
75.1 nM 
Canine in vitro T-cell Proliferation Assay 
T-cell activation plays a key role in a variety of inflamma-
tory and autoimmune disorders as well as asthma, allergies 
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and pruritus. Since T-cell activation can, in part, can be trig-
gered by cytokines that signal through the JAK-STAT path-
way, a JAK inhibitor could be effective against such diseases 
involving aberrant T-cell activation. 
26 
and proinflammatory cytokine receptors could be effective in 
inhibiting, reducing or minimizing flea-associated pruritus 
and dermatitis. 
Study Design 
Twenty eight male and female dogs of mixed breeds rang-
ing in weight from 5-35 kg and greater than one year of age 
were infested with approximately 100 unfed adult cat fleas 
( Ctenocephalides felis) 14 days prior to the start of dosing and 
reinfested with 30 fleas per dog every 4 days throughout the 
study. Seven days before dosing, twenty four dogs were ran-
domized into three different treatment groups, placebo, 0.5 
mg/kg or 0.25 mg/kg of the compound of Example 1 b, based 
15 on visual analog scale (VAS) scores for skin lesions. Treat-
ments were given orally twice a day for 28 days, and pruritic 
Methods: Canine whole blood was collected in sodium 5 
heparin tubes from 29 beagle dogs and 23 mixed breed dogs. 
Whole blood (20 µL) was plated in 96-well plates (Costar 
3598) with 180 µL of medium (RPMI 1640, Gibco #21870-
076, with 1 % heat inactivated fetal bovine serum, Gibco 10 
#10082-39, 292 µg/ml L-glutamine, Gibco #250030-081, 
100 u/ml penicillin and 100 µg streptomycin per ml, Gibco 
#15140-122) containing vehicle control or test compound 
(0.001 to 10 µM), concanavalin A (ConA; 1 µg/ml, Sigma 
C5275), and canine interleukin-2 (IL-2; 50 ng/ml, R&D Sys-
tems 1815-CL/CF). Wells containing whole blood, medium 
with vehicle control and no ConA or IL-2 were used as 
background controls. Plates were incubated at 37° C. for 48 
hours. Tritiated thymidine, 0.4 µCi/well (Perkin Elmer, 
20 
Net027 A-005MC), was added for 20 additional hours. Plates 
were frozen and then thawed, washed and filtered using a 
Brandel MLR-96 cell harvester and prewet filter mats (Wallac 
1205-401, Perkin Elmer). Filters were dried at 60° C. for one 
hour (Precision 16EG convection oven) and placed into filter 25 
sample bags (Wallac 1205-411, PerkinElmer) with l0mL of 
scintillant (Wallac 1205-440, Perkin Elmer). Sealed filters 
were counted on a LKB Wallac 1205 Betaplate liquid scin-
tillation counter. Data were collected via Gterm Betaplate 
30 program vl .1 (Wallac copyright 1989-1990) and transformed 
into percent inhibition, calculated using the following for-
mula: 
behavior as well as erythema and skin lesions were was 
assessed during the study. Pruritic behavior was recorded by 
placing dogs into pens with video recording capability, and 
recording their activity over 4 hours. Pruritic activity was 
quantitated by determining how many seconds the dogs spent 
scratching. Skin lesions were recorded by image capture of 
abdominal, inguinal region and the severity ranked according 
to a visual analog scale (VAS). 
Statistical Analysis: 
Video captured elapsed time of pruritic behavior was ana-
lyzed using a mixed linear model for repeated measures. The 
model included fixed effects of treatment and day of study 
and the interaction of treatment and day of study. Random 
effects included block, the interaction of block and treatment 
and error. Baseline data for pruritic behavior ( day -1) were 
used as covariate in the analysis of pruritic behavior. Least 
35 squares means were used as estimates of treatment means. 
[ 
(Mean Drug Treatment cpm - Mean ECK cpm) l 100- ----------------x 100 = 
(Mean Non-Drug Treatment cpm - Mean ECK cpm) 
% Inhibition 
Standard errors of least squares means were estimated and 
90% confidence intervals were constructed. Geometric 
means were computed from the least squares means for log-
transformed data. A priori contrasts were used to assess treat-
Data were graphically displayed as percent inhibition using 
GraphPad Prism 4.0, and IC50 curves were fitted using a point 
to point analysis. 
40 ment. Treatment differences were assessed at the 10% level of 
significance (Ps0.10). 
Results The average IC50 values obtained when using 
whole blood from beagles was 66.3 nM for the compound of 45 
Example la; 410nM for Example 2; and 83 nM for Example 
Results 
The treatment results are shown in FIG. 2 and FIG. 3. 
Lesions and erythema were significantly reduced in the 0.5 
mg/kg group. FIG. 2 illustrates Day 27 VAS Scores for 
Example 1 b in flea allergic dogs (Least Squares Means). 
Significant reductions in pruritus as compared to placebo at a 
10% level of significance were seen at various time points 
3. The average IC50 value obtained when using whole blood 
from mixed breed dogs was 138 nM for the compound of 
Example la. These data suggest that the compounds of the 
present invention are effective in inhibiting T-cell prolifera-
tion, a key feature in many diseases. 
Example 6 
50 during the study for both groups (days 1, 4 and 12 for the 0.25 
mg/kg dose and on days 1 and 20 for the 0.5 mg/kg dose). 
FIG. 3 illustrates Seconds of Pruritus per 4 hour recording for 
example lb in flea allergic dogs (Long Geometric Mean). 
55 
Reducing Flea-associated Pruritus and Dermatitis Assay 
Flea-associated pruritus and dermatitis are common skin con-
ditions in dogs. Pruritus is one of the most severe clinical 
signs associated with flea associated dermatitis, and contin-
ued scratching, face rubbing, and foot chewing can lead to a 60 
variety of changes to the skin such as erythema, edema, 
alopecia, lichenification, and hyper pigmentation. Flea-asso-
ciated pruritus and dermatitis can be induced experimentally. 
In these models, inflammatory cells and cytokines have been 65 
shown to mediate immune reactions to allergens. Therefore, a 
JAK inhibitor that inhibits signal transduction of pruritogenic 
Example 7 
Cell Proliferation Inhibitory Assay 
Feline Cell Lines The MYA-1 and FETJ are feline T-lym-
phoblast cell lines obtained from ATCC (Manassas, Va.). 
These cells were cultured in RPMI 1640 complete media 
supplemented with 10% FBS at 37° C. in a humidified incu-
bator with 5% CO2 . 
Ex Vivo Canine Lymphoma Nodal Tissue 
Malignant lymph nodes were excised by veterinary staff at 
Michigan State University (MSU) Veterinary College, placed 
US 8,987,283 B2 
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into transport media (Advanced RPMI 1640 complete 
medium supplemented with 10% Fetal Bovine Serum (FBS), 
100 U/mL penicillin, 100 ug/mL streptomycin and 0.25 
ug/mL Amphotercin B (Invitrogen/Gibco®). Nodes were 
processed within 24 hours of removal by mincing into tiny 5 
pieces and passing through a tissue sieve. Cell suspensions 
were spun at 200xg, supernatant was removed, and the cell 
pellet was resuspended in NH4Cl for 10 minutes at room 
temperature. The cell suspension was pelleted by centrifuga- 10 
tion; the NH4 Cl was removed and washed once with Hanks 
Balanced Salt Solution (HBSS), followed by re-suspension in 
Proliferation Medium (Advanced RPMI complete, 1 % FBS, 
50 nM 2-Mercaptoethanol, 100 U/mL penicillin, 100 ug/mL 
streptomycin and 0.25 ug/mL Amphotercin B). The cell sus- 15 
pension was then passed through a 100 µm ny Ion cell strainer 
(BD-Falcon) and counted using a hemacytometer. Cells were 
cultured in either Proliferation Medium alone, Proliferation 
Medium supplemented with 0.005% Pansorbin® (Heat inac-
tivated, formalin-fixed Staphylococcus Aureus cells (SAC), 
Calbiochem), and 10 ng/mL canine IL-2 (R&D Systems), or 
Proliferation Medium supplemented with 125 ng/mL con-
cavalinA (Sigma) and 125 ng/mL lipopolysaccamide (LPS; 
Calbiochem). 
20 
25 
In Vitro Anti-Proliferation Assay Method 
Cells cultured in medium described above were plated in 
96-well Costar plates (Corning) at a density of lxl03 cells/ 
well (feline cell lines) or 2xl 05 cells/well (lymph node cells) 
and exposed to various concentrations oftest compounds for 
up to 5 days at 3 7° C. in a humidified incubator with 5% CO2 . 
Effects on proliferation were determined using the CellTiter 
96® AQueous Non-Radioactive Cell Proliferation Assay 
(Promega) according to manufacturer's instructions. In gen-
eral, proliferation was indirectly measured using a soluble 
tetrazolium salt (MTS) and an electron coupling agent. MTS 
bioreduction into a formazan product soluble in tissue culture 
medium was monitored by absorbance at 490 nM on a Spec-
tramax plate reader using Softmax Pro 4. 6 software (Molecu-
<160> NUMBER OF SEQ ID NOS, 2 
<210> SEQ ID NO 1 
<211> LENGTH, 14 
<212> TYPE, PRT 
SEQUENCE LISTING 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, JAKtide peptide 
<400> SEQUENCE, 1 
30 
35 
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lar Devices). Data were graphically displayed as percent 
DMSO control using GraphPad Prism 4.00, and IC50 curves 
were fitted using a non-linear regression model with a sig-
moidal dose response. 
Results 
Table 4 demonstrates that the compound of Example 1 can 
inhibit proliferation of the feline lymphoid cell line MYA-1 
that is dependent on IL-2 for proliferation, but not an IL-2 
independent line (FETJ). The compound of formula IA or its 
salt can also inhibit proliferation of canine nodal tissue 
obtained from dogs diagnoses with T- or B-cell lymphoma. 
These results suggest a JAK inhibitor may be effective in 
treating canine and feline lymphomas. 
Cell Line or 
Species Lymph Node 
Feline MYA-1 
Feline FETj 
Canine MSULN8 
Canine MSULN8 
Canine MSULN9 
Canine MSULN9 
Canine MSULN 10 
Canine MSULN 11 
TABLE4 
Description 
Lymphoid line 
Lymphoid line 
De nova T-cell 
lymphoma 
De nova T-cell 
lymphoma 
De nova B-cell 
lymphoma 
De nova B-cell 
lymphoma 
Chemotherapy 
resistant B-cell 
lymphoma-
De nova B-cell 
lymphoma 
Stimulant in 
Culture Medium IC50 (nM) 
122 (n - 2) 
>1000 
LPS + ConA 357 
SAC+ IL-2 38 
LPS + ConA 147 
SAC+ IL-2 100 
LPS + ConA 687 
LPS + ConA 64 
Lys Gly Gly Glu Glu Glu Glu Tyr Phe Glu Leu Val Lys Lys 
1 5 10 
<210> SEQ ID NO 2 
<211> LENGTH, 13 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, IRS-1 peptide 
<400> SEQUENCE, 2 
Lys Lys Ser Arg Gly Asp Tyr Met Thr Met Gln Ile Gly 
1 5 10 
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What is claimed is: 
1. A method for treating allergic reactions, allergic derma-
titis, atopic dermatitis, eczema, or pruritus in a mammal com-
prising administering to a mammal in need a therapeutically 
effective amount of a compound of formula I: 
H 
;/;,N-R1 
'-..... 0 
N 
10 
30 
2. The method of claim 1 wherein the therapeutically effec-
tive amount is from 0.01 mg/kg of body weight/day to 100 
mg/kg of body weight/day. 
3. The method of claim 1 wherein the therapeutically effec-
tive amount is from 0.1 mg/kg of body weight/day to 10 
mg/kg of body weight/day. 
4. The method of claim 1 wherein the manmial comprises 
companion animals. 
5. The method of claim 4 wherein the companion animals 
are dogs. 
N::::::"' '\ 15 l I 6. The method of claim 1 wherein the manmial comprises 
N I livestock. 
H 7. The method of claim 1 wherein the compound of formula 
or a pharmaceutically acceptable salt thereof wherein R 1 is 20 I is adminiStered orally, parenterally, or topically. 
C1_4 alkyl optionally substituted with hydroxy. * * * * * 
